Levodrop Hustenstiller

Levodropropizine, the active ingredient in Levodrop Hustenstiller, is a non‑opioid antitussive presented as an oral formulation for oral use. It suppresses dry, non‑productive coughs by acting on sensory nerve endings in the respiratory tract and is intended for adult and adolescent patients who require cough relief without opioid‑related side effects.

GNH USA supplies Levodrop Hustenstiller as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodropropizine is used as a peripheral antitussive to control irritating coughs in the upper respiratory tract.

- Dry cough: reduces the frequency and intensity of cough without sedation. - Non‑productive cough: alleviates cough that does not produce sputum, improving comfort. - Irritative cough: diminishes cough triggered by throat irritation or minor airway inflammation.

Levodropropizine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild stomach upset reported by some users. - Diarrhea: occasional loose stools. - Headache: transient mild headache. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or swelling of the face, lips, or tongue. - Hepatic dysfunction: rare reports of elevated liver enzymes requiring medical evaluation.

Before using Levodrop Hustenstiller, consider the following safety measures.

- Pregnancy: safety not established; discuss risks with a healthcare professional. - Breastfeeding: unknown excretion in milk; consult a physician before use. - Liver impairment: use with caution in patients with hepatic disease. - Concomitant medications: review all current drugs with a pharmacist to avoid interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Levodropropizine may interact with other medicines; monitor accordingly.

Major Interactions (Avoid): - CYP3A4 inhibitors: strong inhibitors could increase levodropropizine plasma levels. - Anticholinergic agents: may enhance anticholinergic side effects.

Moderate Interactions (Monitor Closely): - Other cough suppressants: additive cough‑suppressing effect may lead to excessive suppression. - Sedatives: may increase risk of dizziness when combined.